Skip to content
The Decoder· Manuel Uth·· 26 d ago

OpenAI acquires Orchestra Bio to build AI agents that speed up drug development

OpenAI acquires Orchestra Bio to build AI agents that speed up drug development

AI summary

OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average.

Selection record

Not admittedSum of both 116 < twice the threshold 152

Source tier
Media and individuals; this tier's threshold is 76
Pre-filter
passed:OpenAI收购并构建AI智能体加速药物研发
Same event

A model scores each item twice, independently, against one written standard, out of 100. An item is admitted only when the two scores add up to twice the threshold. The threshold is set per source tier.

Source: The Decoder · the-decoder.com